We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

New Biomarkers May Serve as Companion Diagnostics for Patients Being Treated with IL-2

By LabMedica International staff writers
Posted on 02 Aug 2015
Print article
A transcriptional-profiling study has identified biomarkers related to efficacy of interleukin-2 (IL-2) treatment and has identified patient age as a key determining factor of clinical efficacy.

The study, conducted by Aelan Cell Technologies (San Francisco, CA, USA) and an international team of researchers from Wuhan University (Wuhan, China), Georgia Institute of Technology (Atlanta, GA, USA), Kazakh National Medical University (KazNMU; Almaty, Kazakhstan), the National Center for Cardiovascular Research (CNIC; Madrid, Spain), and PanAmerican Bioinformatics Institute (Santa Marta, Magdalena, Colombia), revealed patient age as a key determining factor in the efficacy of cell-based or pharmacological treatments. The study focused on the effect of age on the interaction of IL-2 treatments with human mesenchymal stem cells (MSCs). It was performed by modeling the aging of MSCs ex vivo, through the process of replicative senescence.

The findings highlight the possibility that in younger patients IL-2s and MSCs work in conjunction to fight cancer; whereas in older patients MSCs no longer work with the immune system and even provide cancerous tumors with a blood supply that aids in tumor invasiveness and metastasis.

As cancer therapies are among the costliest and most toxic pharmacological treatments, the opportunities for more efficient and effective treatment presented by this new information offer possibility to much improve treatment decisions and cost savings. It has the potential to reshape how scientists and physicians look at outcomes of pharmacological interventions, particularly interleukin treatments.

“Our study highlights the importance of age as a factor when designing cell-based or pharmacological therapies for older patients, and it predicts measurable biomarkers characteristic of an environment that is conducive to cancer cells’ invasiveness and metastasis,” said Victoria Lunyak, PhD, a principal investigator for the study and CEO and President of Aelan.

IL-2 is a potent cytokine, boosting the immune system in patients fighting various cancers. As human MSCs work like “internal pharmacies,” the interaction between these cells and IL-2 is critical. Chemicals produced by MSCs can prevent proliferation and promote differentiation of many inflammatory immune cells. With aging, the inventory in these MSCs can change because aging affects MSC-mediated cellular communication circuitry. “We have shown that the IL-2–triggered immunomodulatory-capacity of MSCs could be severely affected by replicative aging,” said co-first author Ping Niu, MD, PhD, associate chief physician, Wuhan University. In fact, genome-wide transcriptional profiling of MSCs from human patients exposed to therapeutic doses of IL-2 showed significant aging-related differences in the transcriptional programs in human stem cells.

“Our computational analysis of transcriptional data sets of MSC response to IL-2 revealed precisely which biological pathways and gene targets are activated in response to drug treatment, all of which could be prioritized for further experimental studies with in vivo models and in clinical settings,” said King Jordan, associate professor, Georgia Tech.

This new study, along with previously published data, is another step toward explaining contradicting reports regarding the tumor-promoting or tumor-suppressing properties of MSCs observed in clinical applications. “Our finding opens the door to development of new companion diagnostics to IL-2 treatment, which will help to select the right patients to undergo IL-2 treatments,” said co-first author Aibek Smagul, KazNMU.

The study, by Niu P, et al., was published July 14, 2015, in the journal Oncotarget.

Related Links:

Aelan Cell Technologies


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.